A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-19

Study Completion Date

2024-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical trial is to learn about a pneumococcal vaccine with a new ingredient (PF-07872411) intended to enhance the effects of the vaccine. This pneumococcal vaccine with the new ingredient may prevent the diseases caused by pneumococcal bacteria like meningitis, sepsis, ear infections and sinusitis.

Meningitis is an infection in which the tissue around the brain and spine is swollen.

Sepsis is a very serious infection in your blood caused by a germ (a bacteria). Sinusitis is when your sinuses (the air-filled spaces inside your nose and head), are infected.

This study is seeking for healthy participants who:

* are above 50 years of age and less than 64 years of age.
* have not taken any vaccine for pneumococcal diseases before.
* have not taken any vaccines with additional ingredients within 1 year before administration of the study vaccine.

All participants will receive a single study vaccine shot in the upper arm muscle at the study clinic. The study will compare the experiences of people receiving the vaccine with a new ingredient in the vaccine to those without the new ingredient. This will be done by comparing 2 different dose levels of the new ingredient. It will also be compared against people who receive the vaccine without the new ingredient and at different dose levels. This will help the study team establish if the vaccine with a new ingredient is safe and effective.

Participants will take part in this study for about 12 months. During this time participants will have up to 6 clinic visits. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these visits.

Some participants will need to have blood taken for laboratory tests before they can be judged to be eligible to be included in the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

NCT06182124

Pneumococcal Disease

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

NCT03313050

Pneumococcal Infections

COMPLETED PHASE2

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

NCT05489328

Pneumococcal Disease

COMPLETED PHASE1

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037

Pneumococcal Infections

COMPLETED PHASE2

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

NCT03835975

Pneumococcal Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose multivalent pneumococcal conjugate vaccine formulation A

Stage 1 - Participants will be randomized to receive a single injection.

Group Type EXPERIMENTAL

Low dose multivalent pneumococcal conjugate vaccine formulation A

Intervention Type OTHER

Biological

Low dose multivalent pneumococcal conjugate vaccine formulation B

Stage 2 - Participants will be randomized to receive a single injection.

Group Type EXPERIMENTAL

Low dose multivalent pneumococcal conjugate vaccine formulation B

Intervention Type OTHER

Biological

Low dose of multivalent pneumococcal conjugate vaccine control

Primary control - Stages 1 and 2 - Participants will be randomized to receive a single injection.

Group Type ACTIVE_COMPARATOR

Low dose of multivalent pneumococcal conjugate vaccine control

Intervention Type BIOLOGICAL

low dose multivalent pneumococcal conjugate vaccine

Standard dose multivalent pneumococcal conjugate vaccine control

Control - Stages 1 and 2 - Participants will be randomized to receive a single injection.

Group Type ACTIVE_COMPARATOR

Standard dose multivalent pneumococcal conjugate vaccine control

Intervention Type BIOLOGICAL

multivalent pneumococcal conjugate vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low dose multivalent pneumococcal conjugate vaccine formulation A

Biological

Intervention Type OTHER

Low dose multivalent pneumococcal conjugate vaccine formulation B

Biological

Intervention Type OTHER

Low dose of multivalent pneumococcal conjugate vaccine control

low dose multivalent pneumococcal conjugate vaccine

Intervention Type BIOLOGICAL

Standard dose multivalent pneumococcal conjugate vaccine control

multivalent pneumococcal conjugate vaccine

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Primary control Control

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participants ≥50 and ≤64 years of age at the time of consent.
* Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including those with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease, within 6 months before receipt of study intervention.
* Female participants of childbearing potential or male participants able to father children and who are willing to use acceptable methods of contraception for at least 28 days after the last dose of study intervention; or female participants not of childbearing potential; or male participants not able to father children.

Exclusion Criteria

* History of a severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component in pneumococcal conjugate vaccines and any other diphtheria toxoid-containing vaccine.
* Serious chronic disorder, including history of metastatic malignancy, severe COPD requiring supplemental oxygen, end-stage renal disease with or without dialysis, cirrhosis of the liver, clinically unstable cardiac disease, or any other disorder, that in the investigator's opinion, would make the participant inappropriate for entry into the study.
* History of microbiologically proven invasive disease caused by S pneumoniae.
* Current febrile illness (body temperature ≥100.4°F \[≥38.0°C\]) or other acute illness within 48 hours before study intervention administration.
* Pregnant female participants or breastfeeding female participants (known or suspected).
* Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation.
* Receipt of any inactivated or otherwise nonlive vaccine within 14 days or any live vaccine within 28 days before administration of study intervention.
* Receipt of an adjuvanted vaccine containing QS-21 (or similar saponin adjuvant), MPL, or MF59 within 1 year before administration of study intervention

Minimum Eligible Age

50 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes